Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. PUNT CJA; VOEST EE; TUENI E; VANOOSTEROM AT; BACKX A; DEMULDER PHM; HECQUET B; LUCAS C; GERARD B; BLEIBERG H
   PHASE IB STUDY OF DOXORUBICIN IN COMBINATION WITH THE MULTIDRUG-RESISTANCE REVERSING AGENT S9788 IN ADVANCED COLORECTAL AND RENAL-CELL CANCER
   British Journal of Cancer
   
   C.J.A. Punt et al., "PHASE IB STUDY OF DOXORUBICIN IN COMBINATION WITH THE MULTIDRUG-RESISTANCE REVERSING AGENT S9788 IN ADVANCED COLORECTAL AND RENAL-CELL CANCER", British Journal of Cancer, 76(10), 1997, pp. 1376-1381
2. SEYMOUR AM; DECAMPOS E; THATCHER N; DEGREVE J; CUNNINGHAM D; HOWELL A; TUENI E; BRON DG; STEWARD WP; BERDEL WE; KNUTH A; LORENZ J; TIMOTHY AR; YVER A; RICHARDS MA
   A SINGLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED DOSE-FINDING STUDY OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR (LENOGRASTIM) IN PATIENTS UNDERGOING CHEMOTHERAPY FOR SOLID CANCERS AND LYMPHOMA
   European journal of cancer
   
   A.M. Seymour et al., "A SINGLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED DOSE-FINDING STUDY OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR (LENOGRASTIM) IN PATIENTS UNDERGOING CHEMOTHERAPY FOR SOLID CANCERS AND LYMPHOMA", European journal of cancer, 31A(13-14), 1995, pp. 2157-2163